

Tullis HEALTH Investors

Contact:

Melanie Oldeman

978.704.9292 (direct)

978.302.0703 (mobile)

moldeman@thi-funds.com

FOR IMMEDIATE RELEASE

Sandford D. Smith Joins Tullis Health Investors As Managing Director

Stamford, Connecticut - January 4, 2011 - Tullis Health Investors (“THI”), a family of funds focused on investments in emerging biopharmaceutical, medical device, medical service and other healthcare companies, announced today the appointment of Sandford D. Smith as a Managing Director, effective immediately. Mr. Smith has served on THI’s Advisory Board since 2008.

Mr. Smith was previously Executive Vice President and President International Group for Genzyme Corporation, where he was a member of the company’s Executive Committee. At Genzyme and as President of the Genzyme International Group for the past several years, Mr. Smith grew Genzyme’s offshore revenue from less than \$100 million to roughly 65 percent of Genzyme’s nearly \$5 billion revenues.

During his tenure, Mr. Smith was responsible for the successful global launch of 12 new products in various therapeutic categories, including rare diseases. Mr. Smith joined Genzyme in 1996, and served as Vice President and General Manager of Genzyme International and President of Genzyme Specialty Therapeutics before being named to his most recent position. Following Sanofi’s acquisition of Genzyme in April of 2011, Mr. Smith was responsible for the integration of Genzyme’s international business into the Sanofi global organization.

Prior to joining Genzyme, Mr. Smith was President and Chief Executive Officer at Repligen Corporation. Under his leadership, Repligen completed several secondary stock offerings, raising more than \$100 million, and established important partnerships with Merck, Eli Lilly, Gillette, and Centocor/Johnson & Johnson. He also held international leadership positions within Bristol Myers Squibb throughout Asia and Japan.

Based in Cambridge, Massachusetts, Mr. Smith has served as a Director on a number of

| [Continued on next page...](#)

boards of both public and private healthcare companies, including Aegerion Pharmaceuticals, Ariad Pharmaceuticals, and BioBehavioral Diagnostics. He currently is a member of the Board of Trustees of Brigham and Women’s Hospital in Boston.

“Sandy’s operational leadership experience, international expertise, relationships throughout the healthcare industry and innovative vision are a valuable addition to THI,” said Jim Tullis, founder and CEO of THI. “He has a successful track record identifying market opportunities, recruiting talent, launching new products and growing companies. Sandy will work both with existing portfolio companies and with the sourcing and development of new investment opportunities, continuing as Chair of the THI Advisory Board. We look forward to his contributions to THI and our investors.”

About Tullis Health Investors

Tullis Health Investors (“THI”) manages a family of funds and investments, each focused exclusively on healthcare. THI has been a pioneer in healthcare-focused venture and growth capital, successfully investing in all major sub-sectors of the healthcare industry over the firm’s 25-year history. THI raised its most current fund in 2010. Recent investments include Sirion Therapeutics, Vidacare, Coherex Medical, Estech, Vital Access, Valeritas, SafeOp Surgical, Exagen Diagnostics, and China MedConnect (CMC). More information can be found at www.thi-funds.com.